(Q38464262)

3 September 2017

Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. (English)

1 reference

3 September 2017

0 references

Ramstad T

1

1 reference

3 September 2017

Lawnicki L

series ordinal

2

1 reference

3 September 2017

Vetto J

series ordinal

3

1 reference

3 September 2017

Weinberg A

series ordinal

4

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

The American Journal of Surgery

3 September 2017

1 reference

3 September 2017

179

1 reference

3 September 2017

400-406

1 reference

3 September 2017

5

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

OX-40: life beyond the effector T cell stage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

V beta CDR3 motifs associated with BP recognition are enriched in OX-40+ spinal cord T cells of Lewis rats with EAE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

The tumor necrosis factor ligand and receptor families.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Fas and FasL in the homeostatic regulation of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC Class I and II expression in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Dendritic cells presenting tumor antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Interleukin-10: a cytokine used by tumors to escape immunosurveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Immunological escape mechanisms in pancreatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2800%2900361-5

10.1016/S0002-9610(00)00361-5

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference